PDS Biotechnology annual free cash flow
2013
2014
2015
2016
2017
2018
2023
2024
2025
PDS Biotechnology Free Cash Flow (FCF) History (PDSB)
PDS Biotechnology reported −$27.8M in free cash flow for fiscal 2025, an increase of $7.3M from the previous fiscal year.
View full PDS Biotechnology company overviewPDS Biotechnology free cash flow by year
| Fiscal year | Period ended | Free cash flow | Change | Growth | FCF margin |
|---|---|---|---|---|---|
| 2025 | 2025-12-31 | −$27.8M | $7.3M | — | — |
| 2024 | 2024-12-31 | −$35.1M | −$1.4M | — | — |
| 2023 | 2023-12-31 | −$33.6M | −$32.1M | — | — |
| 2018 | 2018-12-31 | −$1.6M | $39.3M | — | — |
| 2017 | 2017-12-31 | −$40.9M | −$8.0M | — | — |
| 2016 | 2016-12-31 | −$32.9M | −$9.8M | — | — |
| 2015 | 2015-12-31 | −$23.1M | −$12.5M | — | — |
| 2014 | 2014-12-31 | −$10.6M | −$2.4M | — | — |
| 2013 | 2013-12-31 | −$8.2M | — | — | — |
PDS Biotechnology quarterly free cash flow
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q3.23
Q3.24
Q3.25
| Fiscal quarter | Period ended | Free cash flow | Change | YoY growth | FCF margin |
|---|---|---|---|---|---|
| Q3 2025 | 2025-09-30 | −$5.9M | −$5.5M | — | — |
| Q3 2024 | 2024-09-30 | −$8.0M | −$7.6M | — | — |
| Q3 2023 | 2023-09-30 | −$7.2M | −$6.8M | — | — |
| Q4 2018 | 2018-12-31 | −$317,628 | $9.0M | — | — |
| Q3 2018 | 2018-09-30 | −$432,246 | $11.0M | — | — |
| Q2 2018 | 2018-06-30 | −$415,365 | $8.9M | — | — |
| Q1 2018 | 2018-03-31 | −$404,338 | $10.5M | — | — |
| Q4 2017 | 2017-12-31 | −$9.3M | −$2.9M | — | — |
| Q3 2017 | 2017-09-30 | −$11.5M | −$2.5M | — | — |
| Q2 2017 | 2017-06-30 | −$9.3M | −$906,844 | — | — |
| Q1 2017 | 2017-03-31 | −$10.9M | −$1.7M | — | — |
| Q4 2016 | 2016-12-31 | −$6.4M | $894,884 | — | — |
| Q3 2016 | 2016-09-30 | −$8.9M | −$3.6M | — | — |
| Q2 2016 | 2016-06-30 | −$8.4M | −$2.3M | — | — |
| Q1 2016 | 2016-03-31 | −$9.2M | −$4.8M | — | — |
| Q4 2015 | 2015-12-31 | −$7.3M | — | — | — |
| Q3 2015 | 2015-09-30 | −$5.4M | — | — | — |
| Q2 2015 | 2015-06-30 | −$6.1M | — | — | — |
| Q1 2015 | 2015-03-31 | −$4.4M | — | — | — |
PDS Biotechnology free cash flow growth trends
Over the last five reported fiscal years, free cash flow grew from −$32.9M to −$27.8M, a net increase of $5.1M. PDS Biotechnology's latest reported quarter, Q3 2025, generated −$5.9M in free cash flow, a decrease of $5.5M year over year.
About the metric
What free cash flow means
Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.
Calculation and source
How free cash flow is calculated
TickerStat calculates free cash flow as SEC-reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.
Review PDS Biotechnology filings at SEC.gov ↗